Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abdominal, acute, aftermath, Aileron, Amherst, anticancer, arose, augment, Australia, career, cartilage, characteristic, children, closure, companion, construction, consummate, consummated, Daiichi, debilitating, dense, donut, drawdown, drew, EMA, enlarged, erismodegib, exploratory, ganetespib, gap, Hamermesh, HCl, heavy, histology, hole, incorrect, incurrence, Insight, instability, IRC, Joshua, killing, Kingdom, licensor, liver, logistical, lymphocytic, main, managerial, marrow, Medtronic, MG, misuse, morbidity, mTOR, naive, ocular, outpatient, override, pair, pancytopenia, passion, poor, predecessor, proportionate, proven, reclassification, red, reinterpretation, restoration, rural, Sankyo, saridegib, smoking, spleen, splenomegaly, strain, Switzerland, synergistic, tenant, tobacco, trabectedin, underway, view, vismodegib, white, world
Removed:
absent, affiliate, allocable, allocate, analog, anandamide, Bcl, calculation, ceased, central, chose, colon, commencing, complementary, conversion, correct, defer, demonstrating, divide, expended, exploit, factor, forecast, funded, geldanamycin, GIST, guidance, hematological, Herceptin, immaterial, importantly, infusion, ingredient, kinase, men, met, Modernization, nonqualified, parallel, permission, pharmacodynamic, platform, profit, proper, prostate, refractory, relapsed, relation, reliable, retire, sharing, signaling, strength, trastuzumab, tyrosine, unbenefited, women, Wyeth
Filing tables
Filing exhibits
Related press release
INFIQ similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-173534 and 333-156246, and Form S-8 Nos. 333-167488, 333-164207, 333-156641, 333-151135, 333-145306 and 333-138248) of Infinity Pharmaceuticals, Inc. and in the related Prospectuses of our reports dated March 13, 2012, with respect to the consolidated financial statements of Infinity Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of Infinity Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2011.
/s/ Ernst & Young LLP |
Boston, Massachusetts
March 13, 2012